[Treatment of vegetative disorders caused by commotio cerebri].
D064751:Ammonium Compounds / Q000627:therapeutic use*; D000959:Antihypertensive Agents; D001341:Autonomic Nervous System; D001342:Autonomic Nervous System Diseases; D001921:Brain; D001924:Brain Concussion; D001930:Brain Injuries; D006801:Humans; D010276:Parasympatholytics / Q000627:therapeutic use*; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use*; D014947:Wounds and Injuries; D015016:Yohimbine / Q000627:therapeutic use*
D064751:Ammonium Compounds; D000959:Antihypertensive Agents; D010276:Parasympatholytics; D000644:Quaternary Ammonium Compounds; D046948:Secologanin Tryptamine Alkaloids; D015016:Yohimbine
AMMONIUM COMPOUNDS/therapeutic use; AUTONOMIC NERVOUS SYSTEM/diseases; BRAIN/wounds and injuries; PARASYMPATHOLYTICS/therapeutic use; RAUWOLFIA ALKALOIDS/therapeutic use; WOUNDS AND INJURIES; YOHIMBINE/therapeutic use
Zur Behandlung postkommotionell bedingter vegetativer Dysfunktionen.